Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00532389 · ClinicalTrials.gov registry record · Phase 1
Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple Myeloma
A Phase 1 study of Multiple Myeloma, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
- 16
- Study locations
NCT00532389: Completed Phase 1 study of Multiple Myeloma, sponsored by Novartis Pharmaceuticals.
NCT00532389 is a Phase 1 study of Multiple Myeloma that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 62 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (89% lower). The trial reports 16 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00532389, a Phase 1 study of Multiple Myeloma, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
- 16
- Study locations
Study Summary
This study comprises of a dose-escalation and dose expansion phase and will determine the maximum tolerated dose of oral Panobinostat on a continuous schedule in adult in combination with bortezomib. Safety, tolerability, PK and PD profile of the combined treatments will be assessed as secondary objectives. Dose expansion phase will explore in a non continuous Panobinostat schedule with bortezomib and dexamethasone, safety and tolerability and PK profile of Panobinostat and Bortezomib with and without Dexamethasone
Conditions Studied
Interventions
- DRUG LBH589
Study Locations (16)
Other
- Novartis Investigative Site - Berlin
- Novartis Investigative Site - Kiel
- Novartis Investigative Site - Leipzig
- Novartis Investigative Site - München
- Novartis Investigative Site - Würzburg
Florida
- Innovative Medical Research of South Florida Dept.ofInnovativeMedResearch - Miami Shores
Massachusetts
- Dana Farber Cancer Institute Clinical Research Coordinator - Boston
New Jersey
- Hackensack University Medical Center Multiple Myeloma Division - Hackensack
Washington
- Swedish Medical Center Dept.ofSwedishMedicalCtr. - Seattle
Australian Capital Territory
- Novartis Investigative Site - Canberra
British Columbia
- Novartis Investigative Site - Vancouver
Quebec
- Novartis Investigative Site - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2007-10 |
| Est. Completion | 2013-10 |
| Phase | Phase 1 |
What the finished NCT00532389 record still lists
NCT00532389 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which LBH589 is the first listed.
NCT00532389 lists 16 locations in 12 states (Other, Florida, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT00532389 about?
NCT00532389 is a clinical study titled "Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple Myeloma". This study comprises of a dose-escalation and dose expansion phase and will determine the maximum tolerated dose of oral Panobinostat on a continuous schedule in adult in combination with bortezomib. Safety, tolerability, PK and PD profile of the combined treatments will be assessed as secondary obj...
What is the current status of trial NCT00532389?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2007-10. Estimated completion is 2013-10.
What conditions does trial NCT00532389 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT00532389?
The interventions under investigation include: LBH589 (DRUG).
Who is sponsoring clinical trial NCT00532389?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00532389 being conducted?
This trial has 16 study locations across Florida, Massachusetts, New Jersey, Washington, Australian Capital Territory. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00532389's enrollment target sits among peer trials
62 224th of 438 higher than 214 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03231150 · 62 participants · NA
Plantar Fasciitis Randomized Clinical Control Trial
- NCT03458676 · 62 participants · NA
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
- NCT03596086 · 62 participants · Phase 1
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- NCT03603405 · 62 participants · Phase 1
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia